Artelo Biosciences Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ARTL Nasdaq 8731 https://artelobio.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Artelo Biosciences Inc

Artelo Biosciences Reports Fiscal 2022 Year-End Financial Results and Provides Business Update - Mar 31st, 2023 12:00 pm
Artelo Biosciences to Present at MicroCap Rodeo’s Annual Winter Wonderland – Best Ideas Virtual Investor Conference on February 22, 2023 - Feb 15th, 2023 1:30 pm
Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss - Feb 2nd, 2023 2:00 pm
Artelo Biosciences to Present at Sequire Biotechnology Conference on February 2nd - Jan 26th, 2023 1:30 pm
Artelo Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update - Nov 8th, 2022 1:00 pm
Artelo Biosciences to Present at The LD Micro Main Event XV - Oct 18th, 2022 12:30 pm
Artelo Biosciences to Present at the 2022 Ladenburg Thalmann Healthcare Conference on September 29th - Sep 22nd, 2022 1:00 pm
Artelo Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference - Sep 7th, 2022 12:30 pm
Artelo Biosciences Reports Positive Pre-Clinical Results with its Novel Inhibitor to Fatty Acid Binding Protein 5 - Aug 16th, 2022 1:00 pm
Artelo Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update - Aug 9th, 2022 12:10 pm
Artelo Biosciences Completes Enrollment of the First Three Cohorts in its CAReS Study Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss - Jul 19th, 2022 1:07 pm
Artelo Biosciences Presents Positive Pre-Clinical Results of ART26.12, a Novel FABP5 Inhibitor, in Alleviating Chemotherapy-Induced Pain - Jun 27th, 2022 12:30 pm
Artelo Biosciences Selected for Oral Presentation at the 32nd Annual ICRS Symposium in Galway, Ireland - Jun 24th, 2022 12:30 pm
Artelo Biosciences to Present at the LD Micro Invitational XII on June 7th - Jun 1st, 2022 12:30 pm
36 of the Best Ideas Companies to Present at the Spring into Action - Best Ideas Investor Conference on May 16th - 20th, 2022 - May 16th, 2022 5:20 pm
Artelo Biosciences to Present at the H.C. Wainwright Global Investment Conference on May 24th - May 16th, 2022 12:55 pm
Artelo Biosciences to Present at MicroCap Rodeo’s Spring into Action Best Ideas Virtual Conference on May 16th - May 13th, 2022 12:30 pm
Artelo Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update - May 12th, 2022 12:30 pm
Artelo Biosciences to Present at Investor Summit Group's Q2 In-Person Conference in New York - Apr 26th, 2022 11:33 am
Artelo Biosciences Reports Positive Pre-clinical Results for Lead Program in Cancer-Related Cachexia - Apr 13th, 2022 12:30 pm